374 related articles for article (PubMed ID: 22814742)
1. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate.
Zhang X; Min KW; Wimalasena J; Baek SJ
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2051-60. PubMed ID: 22814742
[TBL] [Abstract][Full Text] [Related]
2. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Different Treatments of (-)-Epigallocatechin-3-Gallate on Colorectal Carcinoma Cell Lines.
Ding YP; Gao ZL; Chen BC; Rakariyatham K; Suo HY; Tong HR; Xiao H
Nutr Cancer; 2018 Oct; 70(7):1126-1136. PubMed ID: 30513211
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines.
De Amicis F; Perri A; Vizza D; Russo A; Panno ML; Bonofiglio D; Giordano C; Mauro L; Aquila S; Tramontano D; Andò S
J Cell Physiol; 2013 Oct; 228(10):2054-62. PubMed ID: 23553645
[TBL] [Abstract][Full Text] [Related]
5. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells.
Bhatia N; Agarwal C; Agarwal R
Nutr Cancer; 2001; 39(2):292-9. PubMed ID: 11759294
[TBL] [Abstract][Full Text] [Related]
6. Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways.
Hung PF; Wu BT; Chen HC; Chen YH; Chen CL; Wu MH; Liu HC; Lee MJ; Kao YH
Am J Physiol Cell Physiol; 2005 May; 288(5):C1094-108. PubMed ID: 15647388
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
8. Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2
Md Nesran ZN; Shafie NH; Ishak AH; Mohd Esa N; Ismail A; Md Tohid SF
Biomed Res Int; 2019; 2019():3480569. PubMed ID: 31930117
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells.
Gupta S; Hussain T; Mukhtar H
Arch Biochem Biophys; 2003 Feb; 410(1):177-85. PubMed ID: 12559991
[TBL] [Abstract][Full Text] [Related]
10. The coffee diterpene kahweol suppresses the cell proliferation by inducing cyclin D1 proteasomal degradation via ERK1/2, JNK and GKS3β-dependent threonine-286 phosphorylation in human colorectal cancer cells.
Park GH; Song HM; Jeong JB
Food Chem Toxicol; 2016 Sep; 95():142-8. PubMed ID: 27424123
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.
Sah JF; Balasubramanian S; Eckert RL; Rorke EA
J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854
[TBL] [Abstract][Full Text] [Related]
12. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma.
Nihal M; Ahmad N; Mukhtar H; Wood GS
Int J Cancer; 2005 Apr; 114(4):513-21. PubMed ID: 15609335
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate regulates the expression of Kruppel-like factor 4 through myocyte enhancer factor 2A.
Ma Y; Shi Y; Li W; Sun A; Zang P; Zhang P
Cell Stress Chaperones; 2014 Mar; 19(2):217-26. PubMed ID: 23884787
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Gong S; Xu D; Zhu J; Zou F; Peng R
Cell Physiol Biochem; 2018; 47(2):680-693. PubMed ID: 29794421
[TBL] [Abstract][Full Text] [Related]
16. EGCG inhibits proliferation, invasiveness and tumor growth by up-regulation of adhesion molecules, suppression of gelatinases activity, and induction of apoptosis in nasopharyngeal carcinoma cells.
Fang CY; Wu CC; Hsu HY; Chuang HY; Huang SY; Tsai CH; Chang Y; Tsao GS; Chen CL; Chen JY
Int J Mol Sci; 2015 Jan; 16(2):2530-58. PubMed ID: 25625511
[TBL] [Abstract][Full Text] [Related]
17. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer.
Sukhthankar M; Yamaguchi K; Lee SH; McEntee MF; Eling TE; Hara Y; Baek SJ
Gastroenterology; 2008 Jun; 134(7):1972-80. PubMed ID: 18549879
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate causes the p21/WAF1-mediated G(1)-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells.
Kim CH; Moon SK
Arch Biochem Biophys; 2005 Mar; 435(2):264-72. PubMed ID: 15708369
[TBL] [Abstract][Full Text] [Related]
19. p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1.
Shen G; Xu C; Chen C; Hebbar V; Kong AN
Cancer Chemother Pharmacol; 2006 Feb; 57(3):317-27. PubMed ID: 16170570
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex.
Lim YC; Cha YY
J Surg Oncol; 2011 Dec; 104(7):776-80. PubMed ID: 21725973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
